Lethean (IntenseCoin) Explained: The Decentralized VPN Cryptocurrency Project

Lethean (IntenseCoin) Explained: The Decentralized VPN Cryptocurrency Project

by Jacob Woods What is Lethean Lethean, incorporated in the UK, has created a decentralized VPN marketplace. Lethean has been described as the “first Mainnet P2P Virtual Private Network backed by the Blockchain.” Users can take advantage of the browser extension or the full client VPN. Anyone can mine the coin or Read More »

 

Pennyheaven Top Picks 2011

No Super 7 this year just my top three picks.
Prices reflect close of business 12/31/10.
Best of Luck and Wishing All of You a Very Happy and Prosperous New Year

1) International Dispensing Corporation IDND.PK .45

IDC is a research and development company that develops and manufactures cutting-edge dispensing solutions, and provides expert supply chain and consulting services, to the food-and-beverage and packaging industries. Its flagship product, The Answer® tap, enables aseptic liquid product to be dispensed from a flexible package over time without compromising the safety of the remaining contents, even without refrigeration.

For more information about IDC, please visit http://www.idcdispensing.com

Latest Quarterly Report: 9/30/2010

Latest News: IDC and PepsiCo Sign Agreement for The Answer

2) Vitro Diagnostics VODG .15

Vitro Diagnostics, Inc., dba Vitro Biopharma owns U.S. patents for production of a fertility drug, immortalization of pituitary cells, and a cell line that produces beta islets for use in treatment of diabetes. Vitro’s mission is “Harnessing the Power of Cells™” for the advancement of regenerative medicine to its full potential. Vitro also owns pending U.S. patents for stem cell therapy of cancer, generation of pluripotent stem cells and is continuously developing patentable cell lines and technologies. Vitro operates within a new high tech and regulatory compliant manufacturing, R&D and corporate facility in Golden, Colorado. Vitro manufactures and sells “Tools for Stem Cell and Drug Development™”, including human mesenchymal stem cells and derivatives, optimized media for sustained self-renewal, lineage-specific differentiation and products supporting induced pluripotent stem cell and cancer research. Vitro recently formed a strategic alliance with HemoGenix®, Inc. to jointly manufacture and distribute Lumenesc™ and LumiSTEM™ assays for quality and potency determination of MSCs, ESC and iPSCs.

For more information about VODG please visit http://www.vitrobiopharma.com

Latest quarterly Report: 7/31/2010

Latest News: New Results Reveal Extensive Competitive Advantages of VitroGrow™ Stem Cell Culture Media

3) WebMediaBrands Inc WEBM 1.63

WebMediaBrands Inc. is an Internet media company that provides content, education, trade shows and online job board services to media and business professionals. The Company’s online business includes: (i) mediabistro.com, a leading blog network providing content, career and educational resources about major media markets and industry verticals including new media, social media, Facebook, TV news, advertising, public relations, publishing, design and mobile; (ii) SemanticWeb.com, providing industry leading content on Semantic Web technology; (iii) Brands of the World, Ads of the World, and other related websites, providing industry leading content for creative, advertising, and design professionals; and (iv) e-commerce websites including Freelance Connect and StockLogos.com. The Company’s trade show and educational offerings include conferences, online and in-person courses, and video subscription libraries on topics covered by the Company’s online business.

Latest quarterly Report: 9/30/2010

Latest News: WebMediaBrands Inc. Announces Plan to Repurchase Shares of Its Common Stock

DISCLAIMER, PLEASE READ

Please be advised that nothing within this notice shall constitute a solicitation or an offer to buy or sell any security mentioned herein. All statements made are our express opinion only and should be treated as such. Nothing within this notice should be considered personalized investment advice. Pennyheaven.com is neither a registered investment advisor nor affiliated with any broker or dealer. Any investments in stocks recommended in this notice should be made only after consulting with your investment advisor and only after reviewing the financial statements of the company. We reserve the right to trade in and out of these stocks at will, before, during, and/or after publication. We have not been compensated by any individual or company and we do not accept any paid promotion. Please do your own DD and trade only what is right for you.

Destiny Media Q2 Revenues Grow 86% Over Prior Year

VANCOUVER, British Columbia, April 14 /PRNewswire-FirstCall/ — Destiny Media Technologies (OTC Bulletin Board:DSNY.obNews) is pleased to announce results for the quarter ended February 28, 2010. Q2 EBITDA was $193,398 on total revenue of $869,864.  During the sixth month period, the company generated net income of $449,849 and EBITDA of $528,109 on revenues of $1,917,392.

The company continues to grow revenue and income through expanded use of the Play MPE® system where revenue during the quarter showed a 106% increase over the same quarter in the prior year.  This growth has been seen across all segments including an increase in North American revenue of 40% and a 535% increase in international revenue. International revenue represents 41% of Play MPE® business for the quarter.

“The increase in our revenue is the result of the continued acceptance of the Play MPE® system which appears to be the system of choice in the industry.  After years of developing the system and network of users, we are very encouraged by the continued increase in Play MPE® revenue.  Each quarter our revenue continues to grow by approximately 100% over the previous year’s quarter.   Over the past three and half years, Play MPE® revenue has grown by an average of 135% higher over the previous year’s quarter and in twelve of those quarters Play MPE® revenue has grown by at least 90%,” said CFO Fred Vandenberg.

A share repurchase program began during the quarter and to date the company has repurchased a total of approximately 520,000 shares for cancellation.  In addition, the company has reduced the number of $0.22 warrants outstanding by 600,000 by way of an exchange  for 336,000 shares and repurchased 150,000 options with a strike price of $.25 for payment of $30,000.

TCCO Reports Results for the First Fiscal Quarter Ended 12/26/09

Technical Communications Corporation Reports Results for the First Fiscal Quarter Ended December 26, 2009

Feb 5, 2010 – CONCORD, Mass.–(BUSINESS WIRE)–Technical Communications Corporation (OTC BB: TCCO.OB – News) today announced its results for the fiscal quarter ended December 26, 2009. For the first quarter of the Company’s 2010 fiscal year, the Company reported net income of $2,356,000, or $1.62 per share, on revenue of $4,764,000, as compared to net income of $206,000, or $0.14 per share, on revenue of $1,844,000 for the quarter ended December 27, 2008. Included in net income for each of the quarters ended December 26, 2009 and December 27, 2008 is $(19,000), or ($0.01) per share, respectively, in stock-based compensation expense.

Click link above for complete article.

Super 7 Update – SPCK and DSNY

1) Superclick Reports Record Revenue and Net Income for the Fiscal Year Ended October 31, 2009 (1/13/09)

2) Destiny Media Q1 Record Revenues Jump 89% (1/14/09)

Pennyheaven Super 7 (2010)

Once again, our main criterion is growth: earnings, sales, and/or revenues must be increasing. The second criterion is profitability. All companies listed are currently profitable. Prices reflect close of business 12/31/09. Best of Luck!

1) Brekford Corp  BFDI (.15)
57,815,513 shares outstanding (s/o) as of 11/2/09
$1.06m cash; 86k debt
9-month sales up 16%
9-month net earnings (+ .01) v (- .03)
Market Cap – $8.67m

Brekford Corp. is a leading homeland technology service provider of fully integrated vehicle installation and rugged technology solutions geared towards mission critical operations. For more than a decade, the company has provided services to branches of the U.S. military, various federal entities and numerous security and public safety agencies. Brekford provides these agencies with an end-to-end suite of mobile products and services designed to streamline procurement and operations.

Brekford 360 Degree vehicle solutions provides complete vehicle upfitting, mobile data and video solutions including municipal financing and leasing services for agencies. The 360 Degree vehicle solutions approach provides customers with a one stop upfitting, cutting edge technology and installation service.

For more Company information, please see website: http://www.brekford.com

2) Biostar Pharmaceuticals, Inc.  BSPM (4.45)
23,240,899 s/o as of 11/10/09
$2.45m cash; 0 debt
9-month net sales up 52%
9-month net earnings (+ .37) v (+ .18)
Market Cap – $103.43m

Biostar Pharmaceuticals, Inc., through its wholly-owned subsidiary in China, develops, manufactures and markets pharmaceutical and medical nutrient products for a variety of diseases and conditions. The Company’s most popular product is its Xin Ao Xing Oleanolic Acid Capsule, an over-the-counter (“OTC”) medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population. In addition to its hepatitis product, Biostar manufactures two broad-based OTC products, two prescription-based pharmaceuticals and thirteen nutrients. The Company has adopted international standards and is in the process of applying for two patents.

3) Destiny Media Technologies  DSNY (.49)
52,059,647 s/o as of 11/26/09
$253k cash, 68k debt
Net income 2009 (+ .01) v (- .05) (2008)
Market Cap – $27.59m

From 10-K (11/30/2009)
Revenue continued to grow during our fourth quarter and was the highest in the Company’s history. Fourth quarter revenue was 77% higher than the same quarter in the prior year and more than 31% above the previous quarter in fiscal 2009. Total revenue for the quarter is $872,569 (third quarter fiscal 2009 – $665,829). Total revenue for the year was $2,560,447 (2008 – $1,578,888), an increase of approximately 62% over the fiscal 2008 year.

Destiny Media (http://www.dsny.com) is the developer of the Play MPE® system (http://www.plaympe.com) which the recording industry uses to securely distribute new pre-release music through the internet to trusted recipients such as radio, media and VIP’s. Real time usage statistics are available at http://www.plaympe.com/v4/company/plaympestats.php

4) Stellar Pharmaceuticals Inc  SLXCF (.98)
23,495,040 s/o as of 9/30/09
$1.91m cash; minimal debt
9-month net revenues up 61%
9-month net earnings (+ .01) v. (- .01)
Market Cap – $23.03m

Stellar Pharmaceuticals Inc has developed and is marketing direct in Canada and in countries around the world through out-license agreements two products based on its core polysaccharide technology: NeoVisc, for the treatment of osteoarthritis; and Uracyst, its patented technology for treatment of interstitial cystitis/painful bladder syndrome, an inflammatory disease of the urinary bladder wall. Stellar also has in-licensing agreement for the distribution and sale of NMP22 BladderChek, a proteomics-based diagnostic test for the diagnosis and monitoring of bladder cancer.

5) Superclick, Inc SPCK (.115)
45,312,251 s/o as of 8/31/09
$1.9m cash; 52k debt
9-month net revenue up 16%
9-month net (+ . 02) v. (+ .01)
Record quarterly revenues for the third quarter ending July 31, 2009
Market Cap – $5.21m

Superclick, Inc. through its wholly owned, Montreal-based subsidiary Superclick Networks, Inc., develops, manufactures, markets and supports the Superclick Internet Management System (SIMS(TM)), Monitoring and Management Application (MAMA(TM)) and Media Distribution System (MDS(TM)) in worldwide hospitality, conference center and event, multi-tenant unit (MTU) and university markets. Current clients include MTU residences and Candlewood Suites, Crowne Plaza, Fairmont Hotels and Resorts, Four Seasons Hotels and Resorts, Four Points by Sheraton, InterContinental Hotels Group PLC, Hilton, Holiday Inn, Holiday Inn Express, Hampton Inn, Mandarin Oriental Hotel Group Marriott, Novotel, Radisson, Sheraton, Westin and Wyndham hotels in Canada, the Caribbean and the United States.
Website: http://www.superclick.com/

6) Technical Communications TCCO (4.10)
1.47m s/o
5.42m cash; 0 debt
Market Cap – $6.02m

For the year ended September 26, 2009, the Company reported revenue of $7,752,000 and net income of $943,000, or $0.65 per share, as compared to revenue of $6,852,000 and net income of $1,061,000, or $0.75 per share, for fiscal 2008. For the quarter ended September 26, 2009, the Company reported net income of $235,000, or $0.16 per share, on revenue of $1,765,000, as compared to a net loss of $(87,000), or $(0.06) per share, on revenue of $1,204,000 for the quarter ended September 27, 2008.

TCC designs, manufactures, and supports superior grade secure communications systems that protect highly sensitive information transmitted over a wide range of data, voice and fax networks. TCC’s security solutions protect information privacy on every continent in over 110 countries. Government agencies, militaries, financial institutions, telecommunications carriers and multinational corporations worldwide rely on TCC to protect their communications networks.

Web Site: http://www.tccsecure.com

7) Tikcro Technologies TIKRF (.92)
~ 8.42m s/o
$7.4m cash; 0 debt
Market Cap – $7.75m

Tikcro Technologies Reports 2009 Third Quarter Results

Net income for the third quarter was $590,000 or $0.07 per diluted share. Net income for the nine months ended September 30, 2009 was $4.7 million or $0.56 per diluted share. Results for the third quarter included financial income of $692,000 primarily from to the valuation of Tikcro’s holdings in BioCancell Therapeutics, Inc., a clinical-stage biopharmaceutical company operating in the area of cancer treatment. Tikcro holds 36% of BioCancell, taking into account the conversion of a convertible note and exercise of warrants, and 27% on a fully diluted basis. Shares of BioCancell are traded on the Tel Aviv Stock Exchange.

Tikcro Technologies has holdings in BioCancell Therapeutics, Inc., a clinical-stage biopharmaceutical company operating in the area of cancer treatment. BioCancell is conducting the following clinical trials in Israel and in the U.S. using its leading drug, BC-819:  – Phase IIb clinical trial for the treatment of superficial bladder carcinoma   cancer – Phase I/IIa clinical trial for the treatment of ovarian cancer – Phase I/IIa clinical trial for the treatment of pancreatic cancer.

DISCLAIMER, PLEASE READ
Please be advised that nothing within this notice shall constitute a solicitation or an offer to buy or sell any security mentioned herein. All statements made are our express opinion only and should be treated as such. Nothing within this notice should be considered personalized investment advice. Pennyheaven.com is neither a registered investment advisor nor affiliated with any broker or dealer. Any investments in stocks recommended in this notice should be made only after consulting with your investment advisor and only after reviewing the financial statements of the company. We reserve the right to trade in and out of these stocks at will, before, during, and/or after publication. We have not been compensated by any individual or company and we do not accept any paid promotion. Please do your own DD and trade only what is right for you.